Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00170989
- Lead Sponsor
- Novartis
- Brief Summary
This study will test the effectiveness and safety of a combination treatment in patients whose blood pressure is not controlled with a single medication.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2714
Inclusion Criteria
- Patients with mild to moderate hypertension
Exclusion Criteria
- Severe hypertension
- History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm
- Liver, kidney, or pancreas disease
- Insulin dependent diabetes
- Allergy to certain medications used to treat high blood pressure
Other protocol-defined exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure from baseline after 8 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in systolic blood pressure from baseline after 8 weeks Change from baseline in standing systolic and diastolic blood pressure after 8 weeks Diastolic blood pressure less than 90 mmHg or at least a 10 mmHg decrease in diastolic pressure after 8 weeks Diastolic blood pressure less than 90 mmHg after 8 weeks Adverse events and serious adverse events at 8 weeks
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇨🇭Basel, Switzerland